These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25974708)

  • 21. Design, synthesis, and testing of potential antisickling agents. 10. (2,2-Dimethylchroman-6-yl)alkanoic acids.
    Fatope MO; Abraham DJ
    J Med Chem; 1987 Nov; 30(11):1973-7. PubMed ID: 3669005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.
    dos Santos JL; Lanaro C; Lima LM; Gambero S; Franco-Penteado CF; Alexandre-Moreira MS; Wade M; Yerigenahally S; Kutlar A; Meiler SE; Costa FF; Chung M
    J Med Chem; 2011 Aug; 54(16):5811-9. PubMed ID: 21766854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK; Kato GJ
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A view of the current status of antisickling therapy.
    Brewer GJ
    Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948
    [No Abstract]   [Full Text] [Related]  

  • 25. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents.
    Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Abdulmalik O; Zhang Y; Safo MK
    J Med Chem; 2020 Dec; 63(23):14724-14739. PubMed ID: 33205981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent insights on the medicinal chemistry of sickle cell disease.
    Dos Santos JL; Chin CM
    Curr Med Chem; 2011; 18(15):2339-58. PubMed ID: 21517749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A structure-guided approach to ameliorate sickle cell disease.
    Richter-Addo GB
    Acta Crystallogr D Struct Biol; 2018 Nov; 74(Pt 11):1039-1040. PubMed ID: 30387762
    [No Abstract]   [Full Text] [Related]  

  • 29. Design, synthesis, and testing of potential antisickling agents. 6. Rheologic studies with active phenoxy and benzyloxy acids.
    Patwa DC; Abraham DJ; Hung TC
    Blood Cells; 1987; 12(3):589-601. PubMed ID: 3651614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 31. The molecular basis of antisickling agents.
    Franklin IM; Huehns ER
    Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
    [No Abstract]   [Full Text] [Related]  

  • 32. Structural Basis of Antisickling Effects of Selected FDA Approved Drugs: A Drug Repurposing Study.
    Olubiyi OO; Olagunju MO; Oni JO; Olubiyi AO
    Curr Comput Aided Drug Des; 2018; 14(2):106-116. PubMed ID: 29380703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regioselective covalent modification of hemoglobin in search of antisickling agents.
    Park S; Hayes BL; Marankan F; Mulhearn DC; Wanna L; Mesecar AD; Santarsiero BD; Johnson ME; Venton DL
    J Med Chem; 2003 Mar; 46(6):936-53. PubMed ID: 12620071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent.
    Iyamu EW; Turner EA; Asakura T
    Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.
    Huang B; Ghatge MS; Donkor AK; Musayev FN; Deshpande TM; Al-Awadh M; Alhashimi RT; Zhu H; Omar AM; Telen MJ; Zhang Y; McMahon TJ; Abdulmalik O; Safo MK
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of pyridine derivatives of L-phenylalanine as antisickling reagents.
    Altman J; Gorecki M; Wilchek M; Votano JR; Rich A
    J Med Chem; 1984 May; 27(5):596-600. PubMed ID: 6716398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covalent inhibitors of the gelation of sickle cell hemoglobin and their effects on function.
    Manning JM
    Adv Enzymol Relat Areas Mol Biol; 1991; 64():55-91. PubMed ID: 2053469
    [No Abstract]   [Full Text] [Related]  

  • 38. Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
    Abraham DJ; Mehanna AS; Williams FS; Cragoe EJ; Woltersdorf OW
    J Med Chem; 1989 Nov; 32(11):2460-7. PubMed ID: 2810334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and testing of antisickling agents. 2. Proline derivatives designed for the donor site.
    Abraham DJ; Mokotoff M; Sheh L; Simmons JE
    J Med Chem; 1983 Apr; 26(4):549-54. PubMed ID: 6834388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells.
    Abdulmalik O; Safo MK; Chen Q; Yang J; Brugnara C; Ohene-Frempong K; Abraham DJ; Asakura T
    Br J Haematol; 2005 Feb; 128(4):552-61. PubMed ID: 15686467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.